SHEN, L., B.R. SHAH, E.M. REYES, L. THOMAS, D. WOJDYLA, P. DIEM, L.A. LEITER, B. CHARBONNEL, V. MAREEV, E.S. HORTON, S.M. HAFNER, Vladimír SOŠKA, R. HOLMAN, M.A. BETHEL, F. SCHAPER, J.L. SUN, J.J. MCMURRAY, R.M. CALIFF a H. KRUM. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ-BRITISH MEDICAL JOURNAL. London: BMJ PUBLISHING GROUP, 2013, roč. 347, f6745, s. 1-11. ISSN 1756-1833. Dostupné z: https://dx.doi.org/10.1136/bmj.f6745.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Autoři SHEN, L. (156 Čína), B.R. SHAH (840 Spojené státy), E.M. REYES (840 Spojené státy), L. THOMAS (840 Spojené státy), D. WOJDYLA (840 Spojené státy), P. DIEM (756 Švýcarsko), L.A. LEITER (124 Kanada), B. CHARBONNEL (250 Francie), V. MAREEV (643 Rusko), E.S. HORTON (840 Spojené státy), S.M. HAFNER (826 Velká Británie a Severní Irsko), Vladimír SOŠKA (203 Česká republika, garant, domácí), R. HOLMAN (826 Velká Británie a Severní Irsko), M.A. BETHEL (826 Velká Británie a Severní Irsko), F. SCHAPER (276 Německo), J.L. SUN (840 Spojené státy), J.J. MCMURRAY (826 Velká Británie a Severní Irsko), R.M. CALIFF (840 Spojené státy) a H. KRUM (36 Austrálie).
Vydání BMJ-BRITISH MEDICAL JOURNAL, London, BMJ PUBLISHING GROUP, 2013, 1756-1833.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 16.378
Kód RIV RIV/00216224:14110/13:00070953
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1136/bmj.f6745
UT WoS 000328574400002
Klíčová slova anglicky diuretic; beta-blocker; statin; diabetes
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 30. 1. 2014 16:55.
Anotace
Objective To examine the degree to which use of beta blockers, statins, and diuretics in patients with impaired glucose tolerance and other cardiovascular risk factors is associated with new onset diabetes. Design Reanalysis of data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Setting NAVIGATOR trial. Participants Patients who at baseline (enrolment) were treatment naive to beta blockers (n=5640), diuretics (n=6346), statins (n=6146), and calcium channel blockers (n=6294). Use of calcium channel blocker was used as a metabolically neutral control. Main outcome measures Development of new onset diabetes diagnosed by standard plasma glucose level in all participants and confirmed with glucose tolerance testing within 12 weeks after the increased glucose value was recorded. The relation between each treatment and new onset diabetes was evaluated using marginal structural models for causal inference, to account for time dependent confounding in treatment assignment. Results During the median five years of follow-up, beta blockers were started in 915 (16.2%) patients, diuretics in 1316 (20.7%), statins in 1353 (22.0%), and calcium channel blockers in 1171 (18.6%). After adjusting for baseline characteristics and time varying confounders, diuretics and statins were both associated with an increased risk of new onset diabetes (hazard ratio 1.23, 95% confidence interval 1.06 to 1.44, and 1.32, 1.14 to 1.48, respectively), whereas beta blockers and calcium channel blockers were not associated with new onset diabetes (1.10, 0.92 to 1.31, and 0.95, 0.79 to 1.13, respectively). Conclusions Among people with impaired glucose tolerance and other cardiovascular risk factors and with serial glucose measurements, diuretics and statins were associated with an increased risk of new onset diabetes, whereas the effect of beta blockers was non-significant.
VytisknoutZobrazeno: 26. 5. 2024 21:49